脑脊液α-突触核蛋白RT-QuIC在路易体痴呆前驱期MCI的诊断价值
该研究应用脑脊液α-突触核蛋白实时震荡诱导转化(RT-QuIC)检测289例来自两个独立队列的样本,评估其对可能由路易体病所致轻度认知障碍(MCI-LB)的识别准确性。结果显示,RT-QuIC区分MCI-LB与认知正常对照的敏感性95%、特异性97%、准确性96%,在神经病理对照中特异性98%。结论认为该检测是前驱期DLB的稳健生物标志物。
要点
- CSF α-syn RT-QuIC对MCI-LB诊断敏感性95%、特异性97%、准确性96%。
- 在神经病理对照中特异性达98%,两队列准确性分别为97.3%与93.7%。
- 13%的MCI-AD患者检测阳性,其中44%随访出现DLB核心或支持性临床特征。
核心结论
- CSF α-syn RT-QuIC是前驱期DLB的稳健生物标志物。
- 该检测有助于准确识别可能由路易体病所致的MCI患者。
研究设计与样本
- 研究纳入两个独立队列共289例脑脊液样本。
- 包括81例可能MCI-LB、120例可能MCI-AD和30例未特定MCI患者。
主要发现
- RT-QuIC区分MCI-LB与认知正常对照的敏感性为95%、特异性为97%、准确性为96%。
- 在神经病理对照中特异性为98%。
- 两队列中MCI-LB检测准确性分别为97.3%与93.7%。
- 13%的MCI-AD患者检测阳性,其中44%随访出现DLB的1项核心或支持性临床特征。
关键数值与推荐
- MCI-LB患者81例,年龄70.7±6.6岁,女性13.6%,MMSE评分26.1±2.4。
- MCI-AD患者120例,年龄68.6±7.4岁,女性45.8%,MMSE评分25.5±2.8。
- 未特定MCI患者30例,年龄65.4±9.3岁,女性30.0%,MMSE评分27.0±3.0。
临床怎么用
- CSF α-syn RT-QuIC可用于前驱期DLB的辅助诊断。
- 对MCI-AD患者检测阳性者需警惕潜在路易体共病理。
局限性
- 需进一步研究充分探讨该检测对现有MCI-LB研究标准的附加价值。
- 本研究证据等级为Class III。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether the CSF α-synuclein (α-syn) real-time quaking-induced conversion (RT-QuIC) assay accurately identifies patients with mild cognitive impairment (MCI) due to probable Lewy body (LB) disease. METHODS: We applied α-syn RT-QuIC to 289 CSF samples obtained from 2 independent cohorts, including 81 patients with probable MCI-LB (age 70.7 ± 6.6 years, 13.6% female, Mini-Mental State Examination [MMSE] score 26.1 ± 2.4), 120 with probable MCI due to Alzheimer disease (AD) (age 68.6 ± 7.4 years, 45.8% female, MMSE score 25.5 ± 2.8), and 30 with unspecified MCI (age 65.4 ± 9.3 years, 30.0% female, MMSE score 27.0 ± 3.0). Fifty-eight individuals with no cognitive decline or evidence of neurodegenerative disease and 121 individuals lacking brain α-syn deposits at the neuropathologic examination were used as controls. RESULTS: RT-QuIC identified patients with MCI-LB against cognitively unimpaired controls with 95% sensitivity, 97% specificity, and 96% accuracy and showed 98% specificity in neuropathologic controls. The accuracy of the test for MCI-LB was consistent between the 2 cohorts (97.3% vs 93.7%). Thirteen percent of patients with MCI-AD also had a positive test; of note, 44% of them developed 1 core or supportive clinical feature of dementia with Lewy bodies (DLB) at follow-up, suggesting an underlying LB copathology. CONCLUSIONS: These findings indicate that CSF α-syn RT-QuIC is a robust biomarker for prodromal DLB. Further studies are needed to fully explore the added value of the assay to the current research criteria for MCI-LB. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that CSF α-syn RT-QuIC accurately identifies patients with MCI-LB.
引用
- Rossi M, Baiardi S, Teunissen CE, et al. Diagnostic Value of the CSF α-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies. Neurology. 2021. PMID: 34210822. doi:10.1212/WNL.0000000000012438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。